Akari Therapeutics Plc (AKTX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Akari Therapeutics Plc is a preclinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs). The company's lead program, AKTX-101, is a Trop-2-targeting ADC currently in IND-enabling activities. The company has no commercial products and has not generated any revenue since inception.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(14.5) million | $(3.7) million |
| Operating Expenses | $15.8 million | $3.5 million |
| Cash and Restricted Cash | $2.8 million | $2.6 million |
| Net Cash Used in Operating Activities | $(2.5) million | $(2.2) million |
| Accumulated Deficit | $(279.0) million | $(251.0) million (approx.) |
| Outstanding Ordinary Shares | 91.6 billion | 57.8 billion (approx.) |
Note: Share counts reflect a significant increase due to a par value change and ADS ratio adjustment effective March 31, 2026.
Material Changes vs. Prior Period
- Significant Impairment Charges: The increase in net loss was primarily driven by non-cash impairment charges totaling $12.1 million. This includes an $8.4 million goodwill impairment and a $3.7 million impairment of the AKTX-101 in-process research and development (IPR&D) asset. These were triggered by a sustained decline in market capitalization and stock price.
- Operating Expenses: Total operating expenses increased by 347% year-over-year, largely due to the impairments. Excluding impairments, cash-based operating expenses decreased slightly.
- ADS Ratio Change: Effective March 31, 2026, the company changed its ADS ratio from 1:2,000 to 1:80,000 ordinary shares to regain compliance with Nasdaq listing rules.
- Stock-Based Compensation: Decreased to $0.3 million from $1.0 million in the prior year quarter.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year. With only $2.8 million in cash, the company estimates its runway extends only into June 2026.
- Funding Needs: The company requires substantial additional financing to fund operations and service obligations. Strategies include equity/debt offerings, strategic collaborations, or asset sales. There is no assurance that funding will be available on acceptable terms.
- Development Timeline: The company projects advancing AKTX-101 into clinical trials by the middle of 2027, pending successful GMP manufacturing and IND-enabling activities.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting (IT general controls and purchase-to-pay processes) which remain unremediated as of March 31, 2026.
- White Lion ELOC: The company has a $25 million Equity Line of Credit (ELOC) with White Lion Capital, but no purchase notices were outstanding as of the reporting date.
Investor Verification Checklist
- Cash Runway: Verify the specific date by which current cash reserves ($2.8M) will be exhausted and the status of any pending financing.
- Impairment Methodology: Review the assumptions used for the $12.1M impairment charge, specifically the discount rates and probability of success for AKTX-101.
- ADS Ratio Impact: Confirm the impact of the 1:80,000 ADS ratio change on share count, liquidity, and potential dilution.
- Internal Control Remediation: Assess the progress of remediation plans for the material weaknesses in financial reporting controls.
- Debt Obligations: Review the terms of the April 2023 Convertible Notes and other debt instruments maturing in 2026.